通化東寶(600867.SH)澄清:公司未入選2019年國家醫保談判目錄結論不成立
格隆匯12月2日丨通化東寶(600867.SH)發佈澄清公告,益盟(全稱:益盟操盤手智盈)“通化東寶未入選2019國家醫保談判目錄”中稱:“2019年國家醫保談判目錄終於在11月28日正式公佈。在150個談判品種中,有91個談判成功,共計18家上市公司的24個創新藥和獨家品種入選,公司未入選。”
針對上述內容公司經調查核實與公司實際情況不符。公司產品重組人胰島素(產品名:甘舒霖)已經進入2019年8月20日由國家醫保局、人力資源社會保障部關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄》《醫保發(2019)46號》,並且處於甲類。因此通化東寶未入選2019年國家醫保談判目錄的結論不成立。
凡進入醫保目錄的產品不需要談判。由於胰島素已經進入到國家醫保目錄,故不需要參與此次醫保目錄的談判,此次醫保目錄談判針對的藥品多為多年來新上市具有較高臨牀價值的藥品,且不在醫保目錄的產品。
“益盟”傳聞給上市公司股價造成巨大影響,該傳聞的內容不屬實,結論不成立,誤導了投資者,給上市公司形象帶來負面影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.